companydata.dkcompanydata.dk

XELLIA PHARMACEUTICALS ApS: Financial statements 2023

CVR: 61094628

Source: annual report 2023, Danish Business Authority

01/01/2023 – 31/12/2023

XELLIA PHARMACEUTICALS ApS (CVR 61094628) has filed annual accounts for 2023. In 2023, the company reported revenue of DKK 1,986,816,000 and a net result of DKK -2,384,901,000 compared with DKK -371,486,000 the year before. That is a decrease of 11.5% compared with the year before. The profit margin was -120%. Equity in the 2023 report amounted to DKK -597,775,000. The company had 650 employees in the financial year.

Revenue
DKK 1,986,816,000
Gross Profit
DKK -640,209,000
Profit/Loss
DKK -2,384,901,000
Equity
DKK -597,775,000
Total Assets
DKK 2,105,002,000
Employees
650

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
20232B-640.2M-2.4B-597.8M650
20222.2B318.4M-371.5M1.8B648
20211.8B-47M-503.1M2.1B640
20202B361.3M-115.7M2.6B624
20192.3B873.5M390.7M1.4B623

Official annual report

View the official annual report directly on the page with a Pro subscription.

Fetch this data via API

Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.

See the API documentation

Events in 2023

John Ramsay Stewart joins the board of XELLIA PHARMACEUTICALS ApSOct 1, 2023

As of October 1, 2023, John Ramsay Stewart has joined the board of directors of XELLIA PHARMACEUTICALS ApS.

Michael Kocher joins the board of XELLIA PHARMACEUTICALS ApSOct 1, 2023

As of October 1, 2023, Michael Kocher has joined the board of directors of XELLIA PHARMACEUTICALS ApS.

Geelanie Rodriguez Briones leaves the board of XELLIA PHARMACEUTICALS ApSOct 1, 2023

As of October 1, 2023, Geelanie Rodriguez Briones has left the board of directors of XELLIA PHARMACEUTICALS ApS.

Carl-Åke Carlsson leaves the board of XELLIA PHARMACEUTICALS ApSOct 1, 2023

As of October 1, 2023, Carl-Åke Carlsson has left the board of directors of XELLIA PHARMACEUTICALS ApS.

Michael Kocher joins XELLIA PHARMACEUTICALS ApS as directorOct 1, 2023

As of October 1, 2023, Michael Kocher is registered as director of XELLIA PHARMACEUTICALS ApS.

Carl-Åke Carlsson steps down as director of XELLIA PHARMACEUTICALS ApSOct 1, 2023

As of October 1, 2023, Carl-Åke Carlsson has stepped down as director of XELLIA PHARMACEUTICALS ApS.

XELLIA PHARMACEUTICALS ApS: The 2022 annual report is outMay 8, 2023

XELLIA PHARMACEUTICALS ApS has published its annual report for 2022. Revenue came to DKK 2,245,303,000, and the net result was DKK -371,486,000.

Gisli Lukas Ihlemann Lundahl leaves the board of XELLIA PHARMACEUTICALS ApSFeb 28, 2023

As of February 28, 2023, Gisli Lukas Ihlemann Lundahl has left the board of directors of XELLIA PHARMACEUTICALS ApS.

Geelanie Rodriguez Briones joins the board of XELLIA PHARMACEUTICALS ApSFeb 6, 2023

As of February 6, 2023, Geelanie Rodriguez Briones has joined the board of directors of XELLIA PHARMACEUTICALS ApS.

Niels Murmann leaves the board of XELLIA PHARMACEUTICALS ApSFeb 6, 2023

As of February 6, 2023, Niels Murmann has left the board of directors of XELLIA PHARMACEUTICALS ApS.

About XELLIA PHARMACEUTICALS ApS

XELLIA PHARMACEUTICALS ApS is a Danish company of the type Anpartsselskab based in København S, founded in 1959. The company is registered under the industry Fremstilling af farmaceutiske råvarer. The company was previously named AXELLIA PHARMACEUTICALS ApS and ALPHARMA ApS. The management consists of Michael Kocher. The board consists of Søren Hostrup (chair), Alexander Sebastian Benjamin Sproedt, Hugo Mendes Marques Crespo Dos Reis and Lars Beck Madsen. The company is owned by XELLIA GROUP ApS. The company has 461 employees (2026). In 2025, the company reported revenue of DKK 1,461,516,000 and a net result of DKK 213,738,000 compared with DKK 828,966,000 the year before. Equity in the 2025 report amounted to DKK 404,569,000.

Source: annual report 2025, Danish Business Authority